ArticleStem cell research & therapy2026
Human adipose-derived mesenchymal stem cells ameliorate Diabetic Kidney Disease by restoring macrophage efferocytosis.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDiabetic Kidney Disease (DKD) is a major complication driven by chronic inflammation and impaired tissue homeostasis. While mesenchymal stem cells (MSCs) show promise, the precise mechanisms by which human adipose-derived MSCs (hASCs) modulate macrophage-mediated resolution of inflammation remain to be fully elucidated.
methodsWe integrated single-cell RNA sequencing (scRNA-seq) analysis of human DKD kidneys with in vivo evaluations in db/db mice and in vitro co-culture models. We employed transcriptomic and molecular approaches to systematically investigate how hASCs impact macrophage functional states.
resultsscRNA-seq revealed a significant dysregulation of phagocytosis and efferocytosis pathways in human DKD macrophages. In vivo, hASCs effectively homed to injured kidneys, improved renal filtration, and attenuated pathological injury. Rather than a simple binary pro-inflammation to anti-inflammatory switch, hASC treatment restored a comprehensive efferocytic program involving multiple functional stages: chemotaxis (GPR132), recognition/engulfment (PARP9, ELMO1, RAC1), and lysosomal digestion/exhaution and polarisation (LAMP1, LIPA, PPAR-γ, ABCA1). This multi-targeted enhancement was accompanied contributed to the efficient clearance of apoptotic cells, reduced renal oxidative stress, and the mitigation of chronic inflammation.
conclusionsOur study systematically delineates the therapeutic benefits of hASCs, suggesting the promotion of macrophage efferocytosis as a significant mechanistic pathway by which hASCs exert their therapeutic effects. Specifically, we demonstrate that hASCs positively regulate key molecular signatures across multiple stages of this process - from "find-me" signal (LPC/GPR132) and "eat-me" recognition (PS/ELMO1) to lysosomal digestion (LAMP1) and subsequent exhaustion and polarisation (LIPA/PPAR-γ/ABCA1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.